Exhibit 99.1
ISIS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS
FOR SECOND QUARTER 2012
· Conference Call Webcast Monday, August 6, 11:30 a.m. ET at www.isispharm.com
CARLSBAD, Calif., August 6, 2012 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma net operating income of $6.2 million for the three months ended June 30, 2012 and a pro forma net operating loss (NOL) of $10.0 million for the six months ended June 30, 2012 compared to a pro forma NOL of $11.6 million and $24.9 million for the same periods in 2011. The significant improvement in the Company’s operating results was driven primarily by the $25 million milestone payment Isis earned from Genzyme when the FDA accepted the new drug application (NDA) for KYNAMRO™ in the second quarter. The Company ended the second quarter of 2012 with $336 million in cash.
“The planned European and United States launches of KYNAMRO™ will be important milestones for Isis and for antisense technology. KYNAMRO™ commercialization will change our financial position by adding commercial revenue to the steady stream of income we receive from our partnerships,” said B. Lynne Parshall, Chief Operating Officer and CFO of Isis. “We have maintained a strong financial position as we have approached this important event while also advancing the rest of our pipeline. We have utilized an innovative and unique business model that has provided us with the cash to expand and mature our industry-leading pipeline. As we look toward the future, in addition to KYNAMRO™ commercial revenue, we have other significant near-term opportunities for continued revenue growth with a wave of potential product launches in the next three to five years. We also look forward to completing clinical studies on several drugs that could be very attractive licensing candidates.”
Upcoming Key Milestones
· Present KYNAMRO™ data at the upcoming European Society of Cardiology highlighting the potential of KYNAMRO™ to reduce the need for lipid-apheresis by lowering LDL-C values below thresholds for apheresis eligibility
· Report clinical data from multiple drugs in Isis’ pipeline, including ISIS-SMNRx, an antisense drug Isis is evaluating in patients with spinal muscular atrophy
· Initiate a clinical study of ISIS-TTRRx in patients with familial amyloid polyneuropathy
· Earn a $25 million milestone payment from Genzyme following FDA marketing approval for KYNAMRO™
· Anticipate marketing approval of KYNAMRO™ in the United States and Europe
Financial Results
On a GAAP basis, Isis reported income from operations of $3.7 million for the three months ended June 30, 2012 and a loss from operations of $14.8 million for the six months ended June 30, 2012 compared to a loss from operations of $14.1 million and $30.2 million for the same periods in 2011.
All pro forma amounts referred to in this press release exclude non-cash compensation expense related to equity awards. Please refer to the reconciliation of pro forma and GAAP measures, which is provided later in this release.
Revenue
Revenue for the three and six months ended June 30, 2012 was $47.3 million and $70.6 million, respectively, compared to $24.8 million and $46.0 million for the same periods in 2011. Isis’ revenue fluctuates based on the nature and timing of payments under agreements with the Company’s partners, including license fees, milestone-related payments and other payments. For example, Isis’ revenue in the first half of 2012 was significantly higher than in the first half of 2011 primarily as a result of the $25 million milestone payment from Genzyme for FDA acceptance of the KYNAMRO™ NDA. Also in the first half of 2012, Isis sold $6.2 million of drug substance to Genzyme to support the planned commercial launch of KYNAMRO™ and began recognizing revenue from the $29 million upfront payment the Company received from Biogen Idec earlier this year. These increases were partially offset when the amortization of the upfront payments associated with the Genzyme collaboration ended in May 2012.
In June 2012, Isis and Biogen Idec entered into a new collaboration and license agreement for the development of a drug to treat myotonic dystrophy (DM1). As part of this collaboration, Isis received a $12 million upfront payment, which Isis will begin amortizing into revenue over five years starting in the third quarter of 2012.
Operating Expenses
On a pro forma basis, operating expenses for the three and six months ended June 30, 2012 were $41.2 million and $80.6 million, respectively, compared to $36.4 million and $70.9 million for the same periods in 2011. The moderately higher expenses in the first half of 2012 were primarily due to higher development costs associated with Isis’ maturing pipeline of drugs offset by lower development expenses related to KYNAMRO™ because Genzyme is now sharing these expenses equally with Isis until KYNAMRO™ is profitable. Genzyme is paying all of the marketing and selling expenses until KYNAMRO™ is profitable.
On a GAAP basis, Isis’ operating expenses for the three and six months ended June 30, 2012 were $43.6 million and $85.3 million, respectively, compared to $38.9 million and $76.1 million for the same periods in 2011.
Net Loss
Isis reported a net loss of $1.2 million and $25.2 million for the three and six months ended June 30, 2012, respectively, compared to $17.9 million and $37.9 million for the same periods in 2011. Basic and diluted net loss per share for the three and six months ended June 30, 2012 was $0.01 per share and $0.25 per share, compared to $0.18 per share and $0.38 per share for the same periods in 2011. Isis’ net loss for the first half of 2012 decreased compared to the same period in 2011 primarily due to a decrease in Isis’ net operating loss offset, in part, by additional non-cash interest expense the Company recorded for the long-term liability associated with its new facility.
Balance Sheet
As of June 30, 2012, Isis had cash, cash equivalents and short-term investments of $336.0 million compared to $343.7 million at December 31, 2011 and had working capital of $295.4 million at June 30, 2012 compared to $284.0 million at December 31, 2011. The decrease in cash in the first half of 2012 primarily relates to cash used to fund Isis’ operations offset by the $25 million milestone payment Isis received from Genzyme and the $29 million upfront payment Isis received from Biogen Idec. Isis’ cash balance at June 30, 2012 does not include the $12 million upfront payment that the Company received in July 2012 from its new collaboration with Biogen Idec to develop and commercialize a drug to treat DM1. Including the $12 million from Biogen Idec, Isis has received more than $875 million from its corporate partnerships since 2007.
Business Highlights
“It has been a very productive first half of 2012 for Isis. We have had many important achievements already this year, including the acceptance of the KYNAMRO™ NDA by the FDA. The KYNAMRO™ NDA filing brings us one step closer to commercializing this important new drug for patients who are at great risk of dying from their cardiovascular disease. KYNAMRO™ represents the first major commercial opportunity for Isis, and we are looking forward to its planned launch in Europe and in the United States,” continued Ms. Parshall.
“We have been very successful with our partnerships, bringing in more than $85 million in cash so far this year. The most significant payment was the $25 million milestone payment we received from Genzyme for acceptance of the NDA filing. We also established a new alliance with Biogen Idec valued at up to $271 million, including the $12 million upfront fee we recently received,” continued Ms. Parshall. “Our new alliance with Biogen Idec allows us to expand our severe and rare disease franchise to include DM1, a devastating neuromuscular disease. This is the second alliance we have established this year with Biogen Idec, and we benefit tremendously from Biogen Idec’s expertise in developing and commercializing drugs to treat neurodegenerative diseases. This expertise complements our ability to discover and develop new antisense drugs to many diseases, including neurodegenerative diseases for which there are limited treatment options and potentially rapid routes to the market.”
“We expect an eventful second half of 2012 as we continue to make significant progress in advancing our pipeline. We anticipate reporting clinical data from a number of drugs in our pipeline, advancing several drugs into later-stage clinical studies and continuing to add new drugs to our pipeline. Of course, KYNAMRO™ will remain center stage. We look forward to sharing news about KYNAMRO™ and the rest of our pipeline as the year progresses,” concluded Ms. Parshall.
Corporate and Drug Development Highlights
· KYNAMRO™ continues to advance in development and move closer to the market for patients with severe forms of familial hypercholesterolemia (FH; homozygous FH and severe heterozygous FH), at high cardiovascular risk, who cannot reduce their LDL-C sufficiently with currently available lipid-lowering therapies.
· The FDA accepted for filing the NDA for KYNAMRO™ for the treatment of patients with homozygous FH.
· Isis received a $25 million milestone payment from Genzyme for the KYNAMRO™ NDA filing.
· A clinical investigator presented an analysis of Lp(a) data from the KYNAMRO™ Phase 3 program at the European Atherosclerosis Society. The data demonstrated sustained reductions of Lp(a), an independent risk factor for cardiovascular disease.
· Isis received European GMP certification of its manufacturing facility for production of drug substance to support KYNAMRO™ commercial launch.
· Isis initiated a Phase 2 study evaluating ISIS-APOCIIIRx in patients with hypertriglyceridemia, a condition characterized by high levels of triglycerides that is often associated with premature coronary artery disease and pancreatitis.
· Isis formed a new strategic alliance with Biogen Idec to develop and commercialize a drug to treat DM1 that expands Isis’ severe and rare disease franchise. Isis received a $12 million upfront payment and is eligible to receive up to an additional $259 million in a licensing fee and milestone payments. Isis will also receive double-digit royalties on product sales.
· Isis and collaborators published a paper in Nature demonstrating that an antisense compound selectively and rapidly reduced target RNA in skeletal muscle and alleviated disease in animal models of DM1.
· Isis and collaborators published a paper in Neuron demonstrating that an antisense compound reversed disease in animal models of Huntington’s disease.
· Isis received Orphan Drug Designation in the U.S. for ISIS-TTRRx for the treatment of TTR amyloidosis.
Conference Call
At 11:30 a.m. Eastern Time today, August 6, Isis will conduct a live webcast conference call to discuss this earnings release and business highlights. Interested parties may listen to the call by dialing 877-556-5921 and refer to passcode “ISIS 2012,” or access the webcast at www.isispharm.com. A webcast replay will be available for a limited time at the same address.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis’ broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer. Isis’ partner, Genzyme, plans to commercialize Isis’ lead product, KYNAMRO™, in the United States and Europe following regulatory approval. Isis’ patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.
Forward Looking Statements
This press release includes forward-looking statements regarding Isis Pharmaceuticals’ financial position and outlook, Isis’ business, and the therapeutic and commercial potential of Isis’ technologies and products in development, including the business of Regulus, Isis’ jointly owned subsidiary. Any statement describing Isis’ goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO™, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, “Isis,” “Company,” “we,” “our,” and “us” refers to Isis Pharmaceuticals and its subsidiaries, including Regulus Therapeutics Inc., its jointly owned subsidiary.
Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc. Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc. KYNAMRO™ is a trademark of Genzyme Corporation.
Isis Pharmaceuticals’ Contacts: D. Wade Walke, Ph.D. Executive Director, Corporate Communications and Investor Relations 760-603-2741 | Amy Blackley, Ph.D. Associate Director, Corporate Communications 760-603-2772 |
ISIS PHARMACEUTICALS, INC.
SELECTED FINANCIAL INFORMATION
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Data)
|
| Three months ended, |
| Six months ended, |
| ||||||||
|
| June 30, |
| June 30, |
| ||||||||
|
| 2012 |
| 2011 |
| 2012 |
| 2011 |
| ||||
|
| (unaudited) |
| (unaudited) |
| ||||||||
Revenue: |
|
|
|
|
|
|
|
|
| ||||
Research and development revenue under collaborative agreements |
| $ | 47,140 |
| $ | 24,305 |
| $ | 68,957 |
| $ | 44,319 |
|
Licensing and royalty revenue |
| 200 |
| 518 |
| 1,618 |
| 1,651 |
| ||||
Total revenue |
| 47,340 |
| 24,823 |
| 70,575 |
| 45,970 |
| ||||
Expenses: |
|
|
|
|
|
|
|
|
| ||||
Research and development |
| 40,435 |
| 36,009 |
| 79,149 | �� | 70,254 |
| ||||
General and administrative |
| 3,209 |
| 2,874 |
| 6,185 |
| 5,884 |
| ||||
Total operating expenses |
| 43,644 |
| 38,883 |
| 85,334 |
| 76,138 |
| ||||
Income (loss) from operations |
| 3,696 |
| (14,060 | ) | (14,759 | ) | (30,168 | ) | ||||
Other income (expense): |
|
|
|
|
|
|
|
|
| ||||
Equity in net loss of Regulus Therapeutics Inc. |
| (163 | ) | (1,033 | ) | (1,139 | ) | (1,889 | ) | ||||
Investment income |
| 477 |
| 616 |
| 1,077 |
| 1,321 |
| ||||
Interest expense |
| (5,219 | ) | (3,437 | ) | (10,398 | ) | (6,851 | ) | ||||
Gain (loss) on investments, net |
| 2 |
| 34 |
| 19 |
| (285 | ) | ||||
Loss before income tax expense |
| (1,207 | ) | (17,880 | ) | (25,200 | ) | (37,872 | ) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Income tax expense |
| — |
| (9 | ) | (2 | ) | (11 | ) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Net loss |
| $ | (1,207 | ) | $ | (17,889 | ) | $ | (25,202 | ) | $ | (37,883 | ) |
|
|
|
|
|
|
|
|
|
| ||||
Basic and diluted net loss per share |
| $ | (0.01 | ) | $ | (0.18 | ) | $ | (0.25 | ) | $ | (0.38 | ) |
Shares used in computing basic and diluted net loss per share |
| 100,213 |
| 99,602 |
| 100,185 |
| 99,586 |
| ||||
Isis Pharmaceuticals, Inc.
Reconciliation of GAAP to Pro Forma Basis:
Condensed Consolidated Operating Expenses and Loss From Operations
(In Thousands)
|
| Three months ended, |
| Six months ended, |
| ||||||||
|
| 2012 |
| 2011 |
| 2012 |
| 2011 |
| ||||
|
| (unaudited) |
| (unaudited) |
| ||||||||
|
|
|
|
|
|
|
|
|
| ||||
As reported operating expenses according to GAAP |
| $ | 43,644 |
| $ | 38,883 |
| $ | 85,334 |
| $ | 76,138 |
|
Excluding compensation expense related to equity awards |
| (2,460 | ) | (2,500 | ) | (4,727 | ) | (5,232 | ) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Pro forma operating expenses |
| $ | 41,184 |
| $ | 36,383 |
| $ | 80,607 |
| $ | 70,906 |
|
|
|
|
|
|
|
|
|
|
| ||||
As reported income (loss) from operations according to GAAP |
| $ | 3,696 |
| $ | (14,060 | ) | $ | (14,759 | ) | $ | (30,168 | ) |
Excluding compensation expense related to equity awards |
| (2,460 | ) | (2,500 | ) | (4,727 | ) | (5,232 | ) | ||||
|
|
|
|
|
|
|
|
|
| ||||
Pro forma income (loss) from operations |
| $ | 6,156 |
| $ | (11,560 | ) | $ | (10,032 | ) | $ | (24,936 | ) |
Reconciliation of GAAP to Pro Forma Basis
As illustrated in the Selected Financial Information in this press release, pro forma operating expenses and pro forma loss from operations were adjusted from GAAP to exclude compensation expense related to equity awards, which are non-cash. Isis has regularly reported non-GAAP measures for operating expenses and loss from operations as pro forma results. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Isis reports these pro forma results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Isis’ pro forma results is consistent with how Isis’ management internally evaluates the performance of its operations.
Isis Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(In Thousands)
|
| June 30, |
| December 31, |
| ||
|
| 2012 |
| 2011 |
| ||
|
| (unaudited) |
|
|
| ||
Assets: |
|
|
|
|
| ||
Cash, cash equivalents and short-term investments |
| $ | 336,029 |
| $ | 343,664 |
|
Other current assets |
| 14,390 |
| 16,475 |
| ||
Property, plant and equipment, net |
| 94,008 |
| 96,615 |
| ||
Other assets |
| 27,967 |
| 28,140 |
| ||
Total assets |
| $ | 472,394 |
| $ | 484,894 |
|
|
|
|
|
|
| ||
Liabilities and stockholders’ equity: |
|
|
|
|
| ||
Other current liabilities |
| $ | 32,065 |
| $ | 39,528 |
|
Current portion of deferred contract revenue |
| 22,998 |
| 36,584 |
| ||
2 5/8% convertible subordinated notes |
| 146,031 |
| 141,448 |
| ||
Long-term obligations, less current portion |
| 79,708 |
| 74,002 |
| ||
Investment in Regulus Therapeutics Inc. |
| 5,563 |
| 4,424 |
| ||
Long-term deferred contract revenue |
| 31,715 |
| 17,474 |
| ||
Stockholders’ equity |
| 154,314 |
| 171,434 |
| ||
Total liabilities and stockholders’ equity |
| $ | 472,394 |
| $ | 484,894 |
|
###